LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)

Authors :: L.M. Itri
T. Goswami
Arjun Vasant Balar
Scott T. Tagawa
Neeraj Agarwal
Daniel P. Petrylak
Phillip L. Palmbos
Philippe Barthélémy
Christos Kyriakopoulos
Aude Flechon
Petros Grivas
Arash Rezazadeh
Y. Loriot
Cora N. Sternberg
P. Beuzeboc
Manojkumar Bupathi
Q. Hong
D. Pouessel
Rohit Jain
Source :: Annals of Oncology. 31:S1156
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
business.industry
Immune checkpoint inhibitors
Cohort
Sacituzumab govitecan
Cancer research
Urothelial cancer
Medicine
Phases of clinical research
Hematology
business

Tools